Feb 07, 2013, 07.20 PM IST | Source: Tech2.com
This is HTCs stop-gap flagship device until it reveals the true successor to the One X or One X+, come MWC.
Last year, HTC surprised us all with the "One" series at the Mobile World Congress (MWC). The flagship of the lot, the One X, is by far one of the best looking handsets of 2012 and HTC plans on repeating that success this year as well. The Taiwanese company recently launched the Butterfly, the international version of the Droid DNA being sold in the US on Verizon’s network. This handset was first launched in Japan as the J Butterfly and had only recently made its way to India and other countries. This is HTC’s stop-gap flagship device until it reveals the true successor to the One X or One X+, come MWC. We are currently in the process of testing this not-so-little critter and will be giving you our first impressions very soon. But before that, let’s take a quick look at what makes this Butterfly so special. With a launch price rivalling the iPhone 5, does it have enough of a "cool factor" to sway buyers from what otherwise would have been an obvious choice at this price range? Let’s find out. OS – Android 4.1 Jelly Bean with Sense 4+ Like all Androids launching this year, the Butterfly has been blessed with the sweet taste of Android Jelly Bean. It’s still 4.1.1, but Jelly Bean nonetheless. HTC is using the latest version of Sense 4+ which made its debut with the One X+ over Jelly Bean. There’s a brand new version in the works though, and we’ll only get to see that in the new "M Series" that will debut at MWC.
READ MORE ON HTC Butterfly, HTC Butterfly review, HTC Butterfly specifications review, HTC Butterfly price, HTC Butterfly price in india, HTC Butterfly launch india, HTC Butterfly buy india, HTC Butterfly best price, HTC Butterfly vs htc one X+, HTC Butterfly vs Samsung galaxy note II, HTC Butterfly vs apple iphone 5, HTC Butterfly droid dna, HTC Butterfly vs HTC M7, HTC, HTC m7, m7, android, sense 5.0, smartphone, mobile phone
ADS BY GOOGLE
video of the day
Gung-ho over pharma; see BPCL rise 30-40% more: Dimensions